How to use and recommended dosage of rasagiline

Rasagilineis an oral monoamine oxidaseB (MAO-B) inhibitor that is widely used as monotherapy or adjuvant treatment for Parkinson's disease. Its pharmacological mechanism lies in selectively inhibiting the activity of MAO-B enzyme in the brain, slowing down the decomposition rate of dopamine, thereby improving the persistence of dopamine signals between neurons. This mechanism makes it one of the important auxiliary drugs for patients who are early or concomitantly taking levodopa.

In monotherapy, the recommended dose of rasagiline is 1 mg daily, usually taken in the morning with or without food. This dose is currently recognized as the optimal starting dose and can significantly improve symptoms in most patients while maintaining good safety. If used as an auxiliary drug in combination with other Parkinson's treatment drugs, the dose should be adjusted according to the specific regimen of the combined drug.

In adjuvant therapy without levodopa, it is still recommended to take 1 mg orally daily. In treatment plans that have already used levodopa, it is recommended to start with 0.5 mg per day and gradually adjust to 1 mg according to disease fluctuations and adverse reactions. The flexible design of this dose helps reduce common problems such as movement fluctuations and side effects, and improves the level of individualization of treatment.

Rasagiline does not require special preparation, and its oral form is simple and suitable for long-term use. However, during medication, care should be taken to avoid combination with certain drugs, such as other MAO inhibitors, pethidine analgesics and certain antidepressants, to prevent serious reactions such as increased blood pressure or serotonin syndrome. In addition, a neurologist must be consulted before changing medications or planning to discontinue medication to avoid "rebound exacerbations" caused by sudden discontinuation of medication.

In summary, the usage principles of rasagiline are fixed dose, regular medication time, and high safety. It plays an important role in the long-term treatment of Parkinson's disease and is one of the effective means to control core symptoms such as tremor, stiffness, and bradykinesia.

Reference materials:https://www.azilect.com/